COMMUNIQUÉS West-GlobeNewswire

NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
02/01/2018
Series A financing co-led by ArrowMark Partners and Barer & Son Capital Financing supports initiation of Phase I/II trial of AIM TM ACT in relapsed/refractory Hematologic Malignancies in 2018 GAITHERSBURG, Md., Jan [...]
Genmab to Present at the 36th Annual J.P. Morgan Healthcare Conference
02/01/2018
Media Release Copenhagen, Denmark; January 2, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 36 th Annual J.P. Morgan Healthcare [...]
Coherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference
02/01/2018
REDWOOD CITY, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS ), today announced that senior management will present at the 36 th annual J.P. Morgan healthcare conference on Monday, [...]
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02/01/2018
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D [...]
Predictive Technology Group Appoints Dr. Michael Dey To Board Of Directors
02/01/2018
SALT LAKE CITY, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK:PRED), announces the appointment of Michael Dey, Ph.D. to the Board of Directors of Predictive Technology Group, Inc. Dr. Dey [...]
Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404
02/01/2018
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today [...]
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
02/01/2018
SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ: CASC ), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric waiver from the European [...]
Sarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
02/01/2018
CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]
BriaCell To Attend Biotech Showcase™ 2018
02/01/2018
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT ) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a [...]
Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications
02/01/2018
WALTHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS ) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External [...]
Peregrine Pharmaceuticals to Present at Biotech Showcase 2018
02/01/2018
TUSTIN, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) (NASDAQ: PPHMP ), a company committed to improving patient lives by manufacturing and delivering high quality biologics, [...]
Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy
02/01/2018
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB ), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding [...]
Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
02/01/2018
-- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- -- FDA sets action date of June 25, 2018 -- SOUTH SAN FRANCISCO, Calif., Jan [...]
Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape
02/01/2018
-- C-Scape was well tolerated across all doses studied in Phase 1 trial, with no drug-drug interaction between the previously approved compounds when dosed in combination -- -- C-Scape is a combination of ceftibuten and [...]
BIOLIFE4D Names Dr. Ravi Birla as its Chief Science Officer
02/01/2018
CHICAGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D , a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Dr. Ravi Birla as its Chief [...]
Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
02/01/2018
Dr. Werner Cautreels Plans Retirement at the End of 2018 Dr. Omid Farokhzad Appointed Chairman of the Board WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB ), a clinical-stage [...]
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
02/01/2018
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive [...]
PositiveID Corporation Discusses 2017 Accomplishments in New Interview with CEOLIVE.TV
02/01/2018
DELRAY BEACH, Fla., Jan. 02, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its Chairman and CEO, William J [...]
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain
02/01/2018
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI ) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that it has [...]

Pages